[go: up one dir, main page]

MX2010004072A - Composicion farmaceutica de orlistat. - Google Patents

Composicion farmaceutica de orlistat.

Info

Publication number
MX2010004072A
MX2010004072A MX2010004072A MX2010004072A MX2010004072A MX 2010004072 A MX2010004072 A MX 2010004072A MX 2010004072 A MX2010004072 A MX 2010004072A MX 2010004072 A MX2010004072 A MX 2010004072A MX 2010004072 A MX2010004072 A MX 2010004072A
Authority
MX
Mexico
Prior art keywords
orlistat
pharmaceutical composition
hydroxypropyl
cellulose
weight
Prior art date
Application number
MX2010004072A
Other languages
English (en)
Inventor
H C Pandey
R B Radhakrishnan
Sariha Farnaaz Mohammed
Dipali Vaghela
Narayana Reddy Lakshmi
Original Assignee
Inventis Dds Pvt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inventis Dds Pvt Ltd filed Critical Inventis Dds Pvt Ltd
Publication of MX2010004072A publication Critical patent/MX2010004072A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Una composición farmacéutica estable que comprende una mezcla de dispersión que comprende 20 a 60% en peso de orlistat y 40% a 80% en peso de vehículo de polímero soluble en agua seleccionado de hidroxipropil metil celulosa, metilcelulosa o hidrixipropil metilcelulosa y similares.
MX2010004072A 2007-10-15 2007-10-15 Composicion farmaceutica de orlistat. MX2010004072A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IN2007/000482 WO2009050720A1 (en) 2007-10-15 2007-10-15 Pharmaceutical composition of orlistat

Publications (1)

Publication Number Publication Date
MX2010004072A true MX2010004072A (es) 2010-09-14

Family

ID=39575576

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010004072A MX2010004072A (es) 2007-10-15 2007-10-15 Composicion farmaceutica de orlistat.

Country Status (4)

Country Link
US (1) US20100317642A1 (es)
EP (1) EP2219614A1 (es)
MX (1) MX2010004072A (es)
WO (1) WO2009050720A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012082083A1 (en) * 2010-12-15 2012-06-21 Les Laboratoires Medis Sa Pharmaceutical formulation containing tetrahydrolipstatin as an active ingredient
CN102362863B (zh) * 2011-11-21 2013-06-12 山东新时代药业有限公司 一种含奥利司他的制剂及其制备方法
CN102552168B (zh) * 2012-01-31 2013-08-07 杭州华东医药集团生物工程研究所有限公司 一种含有奥利司他的药物组合物及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1247547A (en) * 1983-06-22 1988-12-28 Paul Hadvary Leucine derivatives
CA2128044C (en) * 1993-08-05 2007-02-20 Klaus-Dieter Bremer Pharmaceutical compositions comprising a glucosidase and/or amylase inhibitor, and a lipase inhibitor
US6004996A (en) * 1997-02-05 1999-12-21 Hoffman-La Roche Inc. Tetrahydrolipstatin containing compositions
KR100479968B1 (ko) * 1997-02-05 2005-03-30 에프. 호프만-라 로슈 아게 위장 리파아제 억제제의 용도
KR20010079635A (ko) * 1998-08-14 2001-08-22 프리돌린 클라우스너, 롤란드 비. 보레르 리파아제 저해제를 함유하는 약학 조성물
MXPA02012583A (es) * 2000-06-27 2003-04-10 Hoffmann La Roche Metodo para preparacion de una composicion.
JP4265911B2 (ja) * 2000-07-28 2009-05-20 エフ．ホフマン−ラ ロシュ アーゲー 新規医薬組成物
US6730319B2 (en) * 2001-06-06 2004-05-04 Hoffmann-La Roche Inc. Pharmaceutical compositions having depressed melting points
AU2002362061A1 (en) * 2001-12-04 2003-06-17 Biogal Gyogyszergyar Rt Preparation of orlistat and orlistat crystalline forms
DE102004023069A1 (de) * 2004-05-11 2005-12-08 Bayer Healthcare Ag Neue Darreichungsformen des PDE 5-Inhibitors Vardenafil
AU2005247693A1 (en) * 2004-05-25 2005-12-08 Pfizer Products Inc. Tetraazabenzo[E]azulene derivatives and analogs thereof
WO2006104397A1 (en) * 2005-03-26 2006-10-05 Protemix Corporation Limited Copper antagonist compositions
US20060246141A1 (en) * 2005-04-12 2006-11-02 Elan Pharma International, Limited Nanoparticulate lipase inhibitor formulations
ES2374963T3 (es) * 2006-01-05 2012-02-23 Essentialis, Inc. Sales de agentes de apertura del canal de potasio dependiente de atp y usos de las mismas.

Also Published As

Publication number Publication date
EP2219614A1 (en) 2010-08-25
WO2009050720A1 (en) 2009-04-23
US20100317642A1 (en) 2010-12-16

Similar Documents

Publication Publication Date Title
MX2012014849A (es) Acetato succinato de hidroxipropil metil celulosa con substitucion de acetato de y succinato intensificada.
GEAP202112996A (en) Formulations of rifaximin and uses thereof
MY154909A (en) Novel thiophene derivatives
IL197197A0 (en) Oxindole derivatives as anticancer agents
PH12012501905A1 (en) Quinoline derivatives and their use as fungicides
PL1979345T3 (pl) Nowe pochodne pirydyny
IL204437A (en) History of aryl cyclic profile and their use
MX2009008798A (es) Derivados de iminipiridina y sus usos como microbicidas.
TN2010000101A1 (en) Fungicidal 2-alkylthio-2-quinolinyloxy -acetamide derivatives
GEP20156230B (en) Forms of rifaximin and usage thereof
TW200708511A (en) Novel thiophene derivatives
GEP20125702B (en) Benzimidazole derivatives
MX2010005889A (es) Derivados de tiofeno como agonistas de s1p1/edg1.
BRPI0715579A2 (pt) "composto, composição farmacêutica e uso de um composto"
TW200716552A (en) Novel thiophene derivatives
MX2009009774A (es) Derivados de quinolina como fungicidas.
TN2010000061A1 (en) Tricyclic bridged cyclopentanedione derivatives as herbicides
MX2011012739A (es) Derivados fluorados de aminotriazol.
MX2008013040A (es) Derivados de bencimidazol 5-sulfonamida como ligandos del receptor cannabinoide 1.
TW200611904A (en) Aza-bicyclononanes
AU2007249926A8 (en) Monocyclic heteroaryl compounds
MX2013006418A (es) Derivados de oxazolil-metileter como agonistas del receptor de alx.
MX2010009927A (es) Derivados de espiroindolinona.
MX2009011421A (es) Derivados de ftalazina e isoquinolina con actividades moduladoras del receptor de la s1p.
MX2010002245A (es) Derivados de ariloxiacetamida bi o triciclicos, saturados e insaturados y su uso como fungicidas.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal